{"filing":{"accession_number":"0001193125-26-324865","cik":"0001783183","ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"d114879d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879d8k.htm"},"events":[{"id":22039,"run_id":19907,"accession_number":"0001193125-26-324865","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Phathom Pharmaceuticals issued a press release on July 30, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing record Q2 2026 net revenues of $74.3 million (88% increase vs. Q2 2025), operating expenses of $63.1 million (33% reduction), and updated full-year 2026 financial guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21849,"accession_number":"0001193125-26-324865","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Phathom Pharmaceuticals issued a press release on July 30, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing record Q2 2026 net revenues of $74.3 million (88% increase vs. Q2 2025), operating expenses of $63.1 million (33% reduction), and updated full-year 2026 financial guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:08:37.847473+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21849,"accession_number":"0001193125-26-324865","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Phathom Pharmaceuticals issued a press release on July 30, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing record Q2 2026 net revenues of $74.3 million (88% increase vs. Q2 2025), operating expenses of $63.1 million (33% reduction), and updated full-year 2026 financial guidance. This is a standard quarterly earnings release filed under Item 2.02 with the press release attached as Exhibit 99.1.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:08:37.847473+00:00","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-07-30"}]}